Vision & Mission

From bioinformatics analysis
to proteomic validation.

ErVaccine Technologies develops breakthrough immunotherapies combining cancer vaccines and T-cell therapies based on the identification of new families of tumor antigens.

We focus on non-conventional cancer epitopes with the aim of addressing a high medical need in cold tumors not responding to immune checkpoint blockade.

We are dedicated to discover more accurate tumor epitopes that are shared between patients. Our approach is based on new bioinformatics algorithms to identify potential epitopes that are validated by proteomics and immunology assays: from bioinformatics to proteomics.

HISTORY

A biotechnology company
at a preclinical stage

Founded in October 2019 by Prof. Stéphane Depil, financially supported by BPIFrance and a life science investor Seventure (seed investment of 2.5 M€).

Fully integrated in a cutting-edge cancer center and connected to the academic lab “Development of immunotherapies targeting non-conventional tumor antigens” directed by Prof. Stéphane Depil @Cancer Research Center of Lyon (CRCL)/Centre Léon Bérard, with a high-calibre team of experts.

“ ErVaccine Technologies develops cancer vaccines and T cell-based immunotherapies targeting new tumor antigens to address a high medical need in cold tumors. The first candidates are represented by virus-like antigens derived from Human Endogenous Retroviruses (HERVs)”

Stéphane Depil
Stéphane DepilFounder

Company Management

Stéphane Depil
Stéphane DepilFounder, Chairman and CEO
Nathalie Donne
Nathalie DonneHead Business development
Yann Estornes
Yann EstornesDirector of preclinical operations
Philip Parkinson
Philip ParkinsonCFO
Paola Bonaventura
Paola BonaventuraProject leader vaccine programs
Nicolas Chuvin
Nicolas ChuvinProject leader engineered T cells programs
Rasha Boulos
Rasha BoulosHead of bioinformatics and biostatistics

Corporate Board

Stéphane Depil
Stéphane Depil MD, PhD - Chairman
Founder of the company. Onco-hematologist at Centre Léon Bérard and adjunct Professor at University Claude Bernard Lyon 1, former Visiting Professor at King’s College London. Over 15 years of experience in oncology research and drug development both in academia and pharma/biotech as former SVP R&D and CMO at Cellectis, CEO/CMO at Netris Pharma and Head of Oncology R&D at Servier.
Alain Herrera
Alain HerreraMD - Member
Over 25 years of experience in the pharmaceutical industry with a strong focus on oncology drug development and marketing. Supervisory Board member of IDDI, Nanobiotix, PDC*line Pharma, Gustave Roussy-Transfert and Arcad Foundation. Former VP of Global Oncology BD at Sanofi, Chiron Therapeutics
Jérôme Martinez
Jérôme MartinezPharma D, MBA - Member
On the board of Theranexus SA, MDoloris Medical Systems SAS. Former President & CEO of BMI SYSTEM SAS, Senior VP BD for Ethypharm Corp., Chairman-Management Board & CEO at Novagali Pharma SA, Deputy Director at Alliance Santé SA and VP-Marketing & Business Development at Lavipharm Corp.